GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

NextEdge Admin

18 Dec 2024

1 min 18 sec

NeuroKaire, a leader in precision medicine for psychiatry and neurology, has secured $10 million in funding to advance its clinical test for optimizing depression treatment. The funding, led by GreyBird Ventures with participation from Meron Capital and Jumpspeed Ventures, will support scaling operations and expanding pharmaceutical collaborations.

Using its proprietary neuronal readout technology, NeuroKaire analyzes a patient’s unique neurological biomarkers, genetic profile, and medical history to identify the most effective antidepressant or drug combination. This approach eliminates the trial-and-error process of traditional treatment, offering faster recovery, fewer side effects, and lower drug dosages.

In addition to benefiting patients, NeuroKaire’s platform helps pharmaceutical and biotech companies integrate precision medicine into drug development pipelines for psychiatric and neurological diseases. By enabling targeted therapies, NeuroKaire is transforming mental health treatment and improving patient outcomes.